Capturing cell organization in the tumor microenvironment using spatial proteomics can provide insight into the disease. A pair of studies applying this to advanced lung and brain tumors identifies organizational immune hallmarks that are associated with patient outcomes.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Binnewies, M. et al. Nat. Med. 24, 541–550 (2018).
Nat. Methods 19, 259 (2022).
Keren, L. et al. Cell 174, 1373–1387 (2018).
Risom, T. et al. Cell 185, 299–310 (2022).
Sorin, M. et al. Nature 614, 548–554 (2023).
Karimi, E. et al. Nature 614, 555–563 (2023).
Fridman, W. et al. Nat. Rev. Clin. Onc. 19, 441–457 (2022).
Campos, B., Olsen, L., Urup, T. & Poulsen, H. Oncogene 35, 5819–5825 (2016).
Lee, A. et al. Nat. Commun. 12, 6938 (2021).
McDowell, C. Mass Spectrom. Rev. 42, 674–705 (2023).
Haas, P., Hendriks, W., Lefeber, D. & Cambi, A. Front. Chem. 8, 55 (2022).
Li, Chia-Wei et al. Nat. Commun. 7, 12632 (2016).
M.A. and S.C.B. declare that they are founders and paid consultants for Ionpath, the commercial supplier of MIBI spatial proteomic technology. H.P. declares no competing interests.
Rights and permissions
About this article
Cite this article
Piyadasa, H., Angelo, M. & Bendall, S.C. Spatial proteomics of tumor microenvironments reveal why location matters. Nat Immunol 24, 565–566 (2023). https://doi.org/10.1038/s41590-023-01471-8